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Abstract
Background
Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic
and environmental risk factors. An example for the latter is the regular use of combined oral
contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on
estrogen dosage and the type of progestin present in the pill. One out of 1’000 women using
CC develops thrombosis, often with life-long consequences; a risk assessment is therefore
necessary prior to such treatment. Currently known clinical risk factors associated with VTE
development in general are routinely checked by medical doctors, however they are far from
being sufficient for risk prediction, even when combined with genetic tests for Factor V Lei-
den and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific
to the development of thrombosis associated with the use of CC in particular should be
identified.
Methods and findings
Step-wise (logistic) model selection was applied to a population of 1622 women using CC,
half of whom (794) had developed a thromboembolic event while using contraceptives. 46
polymorphisms and clinical parameters were tested in the model selection and a specific
combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 poly-
morphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that
had not been previously associated with the development of thromboembolic event. This
new prediction model outperforms (AUC 0.71, 95% CI 0.69–0.74) previously published
models for general thromboembolic events in a cross-validation setting. Further validation in
independent populations should be envisaged.
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Conclusion
We identified two new genetic variants associated to VTE development, as well as a robust
prediction model to assess the risk of thrombosis for women using combined oral contracep-
tives. This model outperforms current medical practice as well as previously published mod-
els and is the first model specific to CC use.
Introduction
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary
embolism (PE), occurs in 1–2 per 1’000 individuals per year. The incidence increases with age,
from 1 in 100’000 in children to 1 in 10’000 individuals in the reproductive age, 1 in 1’000 indi-
viduals at the age 50 to 60 and 1 in 100 over 75 years old [1]. VTE is a complex multifactorial
disease influenced by several acquired or inherited conditions. The acquired conditions include
a large number of risk factors such as surgery and trauma, prolonged immobilization, cancer,
myeloproliferative disorders, and even pregnancy and post-partum [2]. Weight, age, smoking
status and hormonal treatment are all additional environmental factors associated with an
increased risk of VTE.
The inherited conditions include mutations in the diverse well-known clotting anticoagu-
lant or thrombolytic factors genes, such as the Factor V Leiden (F5) gene, and the prothrombin
Factor II (F2) gene. Such mutations can also be present in genes coding for proteins C and S,
however despite the fact that they increase the risk of developing venous thrombosis signifi-
cantly, they are rare and most of them are practically private [3]. Other likely inherited causes
include a possible increase in the expression of procoagulant factors such as factor VIII, von
Willebrand factor, and factors IX and XI [4]. In addition, non-O ABO blood groups, with the
exception of the A2 group, were demonstrated to increase the risk of developing thrombosis.
Many other additional genetic variants, present in the genes FGG, GP6, KNG1, PROCR,
SLC44A2, STXBP5 and TSPAN15, among others, were associated with an increased risk of
venous thrombosis [5].
Over 100 million women worldwide use combined estroprogestative contraceptives (CC),
due to their very high effectiveness in reducing the risk of unwanted pregnancy and their bene-
ficial effect on diverse symptoms related to women’s cycle. Nonetheless, these contraceptives
also increase the risk of blood clotting substantially, which can ultimately lead to DVT and PE
[6]. Newer generations of CC, the so-called 3rd and 4th generation CC (pills containing nor-
gestimate, gestodene, desogestrel or drospirenone as progestin), are usually better tolerated by
women but importantly, they increase the risk of developing VTE even more than the older
preparations of the so-called 2nd generation (levonorgestrel containing-pills).
The incidence of thrombosis among CC users is around 1‰ per year [7]. In France alone,
where over 3 million women aged 15–49 use CC, the National Agency for the Safety of Drugs
and Health Products reports every year over 2’500 cases of DVT, 850 cases of PE, and 20 cases
of death linked to contraceptive pills. Taking into account the incidence of thrombosis among
contraceptive pill users and number of women using them, it is estimated that 22’000 DVT
related to CC occur each year in Europe. Thus, one of the major challenges for healthcare pro-
fessionals is to identify women at risk of developing blood clotting disease related to CC such
as DVT and PE, and advise them on alternative contraception methods.
As the standard of care nowadays, prescribing physicians assess the risk of thrombosis
using clinical parameters, mostly focusing on age, body mass index, smoking habits and
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personal and familial history of DVT or related diseases that are known risk factors for VTE
development. However, diverse studies demonstrate that clinical informations, notably famil-
ial history, are insufficient to reliably estimate risk of VTE [8, 9]. When the familial history of
thrombosis is positive, physicians might use the first-level laboratory test for thrombophilia
screening that includes analysis of only 2 genetic risk factors: the F5-Leiden and the F2 muta-
tions; eventually, some laboratories, also include genetic tests allowing to assess for the ABO
blood group. Widely-accepted evidence of haemostatic abnormalities associated with throm-
bophilia includes the following parameters: antithrombin deficiency, protein S deficiency, pro-
tein C deficiency, F5-Leiden mutation, F2 mutation, non-O ABO blood group and high levels
of factor VIII dysfibrinogenaemia [10]. Though F5-Leiden and F2 mutation are well-estab-
lished risk factors for thrombosis development, they explain less then one third of the inherited
risk to develop thrombosis. Precisely, F5-Leiden is present among 20% of patients that develop
thrombosis, whereas only 6% of patients carry the F2 mutation [10]. Therefore, genomic asses-
sement that takes into account other polymorphisms associated with VTE development is
mandatory.
Materials & methods
Population studied
The population described in this study has been designed to investigate the clinical and genetic
factors that affect the risk of VTE in women taking CC. The study includes 794 female cases
who have developed at least one episode of VTE while taking CC. These cases are part of the
previously described PILl Genetic RIsk Monitoring (PILGRIM) study [11], in which the
method used to confirm the occurence of thrombosis is defined. 828 control women were also
collected from different sources: 523 are part of the PILGRIM study; 174 are part of the CoLaus
study [12], 56 were recruited between 1997 and 1998 in south of France among healthy volun-
teers and the remaining controls were recruited by established medical clinicians between
2012 and 2016 among Swiss population. The last two groups of controls include any woman of
childbearing age who was using CC at the time of collection and did not have a thrombotic
event prior to sample collection time. These women were not recruited as part of thrombophi-
lia screening and are unrelated to thrombotic patients. Nonetheless some of them have
described a family history at the time of collection (19/128). The PILGRIM study controls pre-
sented a selection bias due to having been recruited as part of thrombophilia screening due to
family history [11] and several variables (family history, F5 and F2) were not used as such, as
described below. All control women are taking CC but have not developed VTE by the time of
the genotyping investigation. This study involved human subjects and was carried out in
accordance with the tenets of the Declaration of Helsinki; all participants signed an informed
consent and data were anonymised. The procedures regarding the collect of PILGRIM samples
were reviewed and approved by the Assistance Publique des Hopitaux de Marseille insitutional
review committee. The CoLaus study was approved by the Ethics Committee of Lausanne
University.
Genotyping
46 SNPs were selected according to their association with VTE development or hormone
metabolism (principaly estrogens) as described in the literature. These 46 SNPs were geno-
typed using Illumina GoldenGate technology and assessed using Illumina BeadXpress and
GenomeStudio V2011.1 software. Clusters for each SNP were curated manually and undeter-
mined samples were further genotyped using Sanger sequencing. SNP rs1053878 was geno-
typed using RFLP-PCR; in more details, the DNA region was amplified with the following
Thrombosis risk and contraception
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primers (Forward: 5’-GCCACCGTGTCCACTACTATG-3’ and Reverse: 5’- GTCCACGCA
CACCAGGTAAT-3’) and the amplicons were digested with PvuII restriction enzyme. Con-
trols from the CoLaus cohort were previously genotyped as described [13]. For the CoLaus
controls, proxys (r2> 85%) were used for 9 SNPs (rs4572916 for rs10029715, rs8176704 for
rs1053878, rs3736455 for rs13146272, rs6018 for rs1800595, rs4253417 for rs2289252, rs110
38993 for rs3136516, rs2169682 for rs7082872, rs687621 for rs8176719 and rs2069952 for
rs9574). Genotyping data for rs1799963 was missing in the CoLaus study. Genotpying data for
rs6025 and rs1799963 of the 523 control samples from the PILGRIM study were ignored to
avoid selection bias due to having been recruited as part of thrombophilia screening due to
family history [11]. Allele frequencies of the 46 SNPs in the controls were consistent with the
ones observed in the European subsample of the 1000 Genomes panel [14].
Clinical characteristics
Age and smoking status were determined at the time of VTE for cases and at the time of DNA
collection for controls. BMI was dertermined at the time of consultation for both cases and
controls. Family history was defined as positive when at least one first-degree relative has suf-
fered VTE. Information on family history for the 523 control women from the PILGRIM
study was not used as such because of the recruitment bias [11]. All women included in this
study took oral combined contraceptive.
Statistical analyses
The study population was randomly divided 10’000 times into a training set and a test set of
equal size. For every sample split missing values were imputed by a random draw from the
non-missing values present in the control samples. Once missing values were imputed, we
applied step-wise logistic regression model selection (as long as the Akaike Information Crite-
rion (AIC) was improved) to each training set to select variables and assign coefficients. The
fitted model was then applied to the test sets to estimate the predictions of the model in an
out-of-sample setting. Across the 10’000 runs the average number of selected variables was
18.1. Two variables were selected over 99.9% of the time (rs6025 and rs1799963). When a run
did not select a variable (i.e. we had no evidence that the coefficient is significantly different
from zero) its coefficient was set to zero, equivalent to an odds-ratio of 1. The final model coef-
ficients are estimated as the median values of the coefficients across the 10,000 runs. This
model consists of 13 variables (including 9 SNPs) with non-zero median values. The corre-
sponding standard error (SE) for each of the 13 coefficients is the median standard error across
those runs (out of the 10,000) when the variable was selected into the model. Confidence inter-
vals and p-values were derived from the coefficients and standard errors (SEs) in the standard
manner.
We compared our 9-variable genetic prediction model (including only SNPs) to previously
published genetic models [8, 15]. For a fair evaluation, in each random data split (and imputa-
tion) the coefficients of each model (including our 9-variable genetic model) were estimated in
the training set and the predictions were evaluated in the test set based on the Area Under the
receiver operator characteristic Curve (AUC). AUC is equal to the probability that the predic-
tor value of a positive test ranks higher than that of a negative test in order to discriminate the
women at risk to the women without risk. The AUC ranges from 0.5 (50%—no predictive
value) to 1 (100%—perfect discrimination) [16].The final AUC for each model is its median
AUC across the 10,000 random data splits.
Thrombosis risk and contraception
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Results
The clinical characteristics of the population of women taking CC described here are defined
in Table 1. Age distribution is similar between cases and controls as demonstrated by Wil-
coxon rank-sum test (p-value = 0.1). Five parameters are statistically different between both
populations, including 3 clinical variables (BMI, family history and smoking status) and two
thrombophilia markers, FV-Leiden and prothrombin (F2). Although we cannot demonstrate
that these differences are not due to selection bias, all five characteristics are known risk factors
for VTE development, thus the minor observed differences are not surprising. The modest dif-
ferences observed in our samples reinforce the current evidence that clinical information is
not sufficient to distinguish women at risk to develop VTE [8, 9].
46 SNPs selected according to their association with VTE development or hormone metab-
olism (principaly estrogens), as described in the literature, were successfully genotyped in the
1622 women involved in this study. Familial history and genotyping data of rs6025 and
rs1799963 of 523 control women were treated as missing in order to avoid an ascertainment
bias. To make sure that the frequency of each SNP in our control population corresponds to
the frequencies expected in a general Caucasian population, we compared the allele frequen-
cies (AF) observed in our control population to the ones reported in 1000 genomes project
[14]. The frequencies were similar (S1 Table, Fisher p-values > 0.01) for all but two SNPs
(rs1593812 and rs429358, which were discarded from further analysis) suggesting that our
Table 1. Clinical characteristics of the population.
Cases (n) %/SD Controls (n) %/SD p-value6
Total number 794 49% 8281 51%
VTE 794
DVT 600 75.5%
PE 194 24.5%
Age (mean) 32 [17–49] + SD: ± 9.6+ 31.5 [18–51] + SD: ± 9.0+ 0.1
BMI (mean) 24 [18–37] + SD: ± 5.2+ 23 [17.5–33.5] + SD: ± 4.2+ 6.6E-06
Family history of VTE 222 28% 19(317)2 15(38)2% 1.7E-03
Smoking 260 33% 206 25% 4.7E-04
Cancer 6 0.7% 23 0.2% 0.4
Autoimmune disease 8 1% 43 0.7% 0.65
Thrombophilia factors:
Protein C 20 2.5% 73 1.6% 0.1
Protein S 10 1.2% 123 0% 0.15
Antithrombin 6 0.8% 21 0.5% 0.4
F5-Leiden 132 16.5% 10(98)4 3(13)4% 3.3E-09
Prothrombin (F2) 80 10% 3(64)5 2(8)4% 3.8E-03
+ 95%CI (in brackets) and Standard deviation (SD) are indicated for these parameters
1 The total number of controls differs depending on the variable as indicated in 2 and 3.
2 This variable was set as missing or was missing for 700 control women as indicated in M&M and the total number of controls used here is 128 controls.
The number indicated in brackets is the original number before correction for bias.
3 This parameter is missing for 305 control women.
4 This variable was set as missing for 523 control women as indicated in M&M and the total number of controls used here is 305 controls. The number
indicated in brackets is the original number before correction for bias.
5 This variable was set as missing for 697 control women as indicated in M&M and the total number of controls used here is 131 controls. The number
indicated in brackets is the original number before correction for bias.
6 p-values calculated using Wilcoxon rank-sum test to compare cases to controls.
https://doi.org/10.1371/journal.pone.0182041.t001
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control population reflects a general Caucasian population and that the genotyping is of high
quality.
Logistic regression models were fitted step-wise to find the optimal (in terms of AIC) multi-
variate model in the 10,000 training sets. By averaging these 10,000 models, we identified 4
clinical variables as risk factors contributing to the prediction of the risk of VTE in our popula-
tion. Age, BMI, smoking status and family history were selected and had significant p-values
(Table 2, p-values < 0.05). 9 out of the 44 tested SNPs were in the averaged model and also sig-
nificantly associated with the development of thrombosis (Table 2). The reported p-values sur-
vive 5% false discovery rate (FDR) control. Among these nine SNPs, as expected, F5-Leiden
(OR = 6.46, CI = [3.46–8.37]) and F2 (OR = 5.32, CI = [2.66–7.9]) mutations are long-known
risk VTE factors. Further five SNPs including rs2289252 (F11), rs710446 (KNG1), rs9574
(PROCR) and rs8176719/rs8176750 (tagging ABO subtypes) have been recently associated
with VTE (Table 2) [17–20]. The final two of the nine polymorphisms, rs1799853 (CYP2C9)
and rs4379368 (SUGCT), have not been described before to impact VTE development. No
interactions among selected parameters were identified to be significant.
We estimated the out-of-sample performance of the set of 13 combined parameters as well
as the clinical- and genetic-only models separately (Pill Protect1 models). The ROC curves
for the clinical, genetic and combined models are represented in Fig 1. The clinical model
gives an AUC of 0.61 (0.58–0.64) and the genetic variables alone give an AUC of 0.68 (0.65–
Table 2. Clinical and genetic parameters selected in the Pill Protect®model.
Variable Gene (when
applicable)
Effect allele (when
applicable)
Mean (frequency)
among cases
Mean (frequency) among
controls
OR 95% CI p-value
Family history of
VTE
281 151 2.13 1.61–
2.83
1.4E-07
Smoking 331 251 1.63 1.27–
2.09
1.3E-04
BMI 242 232 1.07 1.04–
1.09
3.2E-07
Age 322 31.52 1.01 1.001–
1.03
0.03
rs6025 F5 A 0.09 0.02 6.46 4.04–
10.3
5.8E-15
rs1799963 F2 A 0.05 0.01 5.32 3.01–
9.31
7.39E-
09
rs8176719 ABO I 0.50 0.41 1.52 1.28–
1.80
1.71E-
06
rs2289252 F11 T 0.49 0.42 1.34 1.14–
1.58
3.5E-04
rs1799853 CYP2C9 T 0.15 0.12 1.54 1.21–
1.94
3.5E-04
rs9574 PROCR G 0.57 0.51 1.25 1.07–
1.47
0.0052
rs8176750 ABO D 0.05 0.07 0.60 0.42–
0.85
0.0043
rs4379368 SUGCT T 0.11 0.08 1.35 1.03–
1.80
0.032
rs710446 KNG1 G 0.46 0.43 1.22 1.04–
1.43
0.016
1 Percentage of cases and controls with the corresponding clinical factor
2 Mean of the corresponding clinical factor across the cases or controls
https://doi.org/10.1371/journal.pone.0182041.t002
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0.71). Combining both clinical and genetic parameters increase the AUC to 0.71 (0.69–0.74).
To compare these results with the current best practice, based on an oral anamnesis of the
patient, we estimated coefficients for the clinical variables from a meta-analysis of the literature
using weighted means (S2 Table, MD algorithm). In some cases, medical doctors may request
a thrombophilia status that includes the genotyping information for F5-Leiden and F2 muta-
tions (rs6025 and rs1799963). We, therefore, also compared our model to a model that con-
tains the previous clinical variables and coefficients for these two SNPs obtained from the
literature (S2 Table, MD-gen algorithm). The MD model reached an AUC of 0.61 in our stud-
ied population that is similar to our clinical-only model. After adding genetic information to
the MD model, the MD-gen model reaches an AUC of 0.67 in our studied population. Our
combined model achieved significantly higher performance than any model we could derive
from the literature (Table 3).
Fig 1. ROC (AUC) curves for Pill Protect models. The clinical (dashed line), genetic (dotted line) and
combined models (black line) are indicated. The light grey line represents the reference line (AUC 0.5).
https://doi.org/10.1371/journal.pone.0182041.g001
Table 3. Out-of sample AUC values for various published- and our models applied to our studied
population.
Model AUC 95% CI
Pill Protect® clinical model 0.61 0.58–0.64
Pill Protect® genetic model 0.68 0.65–0.70
Pill Protect® combined model 0.71 0.69–0.74
MD model 0.61 0.60–0.62
MD-gen model 0.67 0.66–0.68
Bruzelius genetics 0.65 0.63–0.68
De Haan genetics 0.64 0.62–0.68
https://doi.org/10.1371/journal.pone.0182041.t003
Thrombosis risk and contraception
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Previous studies have modelled VTE risk using different combinations of parameters
although none are specific to the use of CC. Because the whole set of clinical parameters used
by the other models was not available, we compared only the genetic models. The genetic
score described by De Haan et al. [8] is based on 5 SNPs (rs6025, rs1799963, rs8176719,
rs2066865, rs2036914). All of these SNPs are present in our current study, although only 3 of
them are used in our final model. Applying this 5-SNP model to our population yielded an
AUC of 0.64 (0.62–0.68) (Table 3 and Fig 2), which is less than the described AUC on MEGA
and LETS cohorts (0.69 and 0.67 respectively) due to winners curse. The genetic score
described by Bruzelius et al. [15] is based on 7 SNPs (rs6025, rs1799963, rs514659, rs2289252,
rs1799810, rs710446, rs2066865) and 4 interactions. Among the 7 SNPs, 4 are present and one
(rs514659) has a good proxy (rs8176719) in our Pill Protect1 model, and one (rs2066865) is
not part of our model but is present in our dataset. The last SNP (rs1799810) is absent from
our dataset and was, therefore, not used in the comparison. However, given the small (and
least significant) coefficient reported by Bruzelius, it would probably not affect significantly
the performance. This is confirmed by the fact that genetic score associated with this set of six
SNPs reaches an AUC of 0.65 (0.63–0.68) in our study (Table 3 and Fig 2), which is very simi-
lar to what was described by Bruzelius et al. (0.66; [0.64–0.68]). Still both AUC values are sig-
nificantly below the 0.68 AUC of our 9-SNP genetic model.
Discussion
In this study, we determined a new combination of parameters that predicts the risk of VTE in
women using CC. This combination outperformed significantly previously published models
Fig 2. ROC (AUC) curves for the Pill Protect® and published genetic models. The models described in
De Haan et al. (dot-dashed line), in Bruzelius et al. (long dashes) and in this paper (dotted line) are indicated.
The light grey line represents the reference line (AUC 0.5).
https://doi.org/10.1371/journal.pone.0182041.g002
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as well as the clinical evaluation currently used by medical doctors. We also identified two new
genetic markers associated with the development of VTE in our population.
The risk of VTE development upon CC use is presently assessed by an oral anamnesis and
based on physician’s experience. In the presence of clinical risk factors and/or family history,
some medical doctors may request a thrombophilia status that tests for the well-established
markers FV-Leiden and Prothrombin. The current incidence of 1‰ of VTE per year in CC
users indicates that the risk assessement needs to be improved. Analysing genetic and clinical
data for a population of women using CC, we were able to calculate a risk score that outper-
foms a model that simulates the current empirical approach even when combined with addi-
tional information on FV-Leiden and Prothrombin. Our predictor Pill Protect1, including 9
genetic markers in combination with 4 clinical factors, was able to reach an out-of-sample
AUC of 0.71. The use of these 9 genetic markers also outperformed the combination of mark-
ers previously published by others [8, 15]. A thrombophilia status would be complementary to
the risk score approach described here, as a functional test in the presence of clinical suscpis-
cion, in order to take into account rare mutations such as the one present in Protein S, Protein
C or Antithrombin genes.
Our study presents some limitations regarding the identification of rare polymorphisms
and rare mutations due to the size of the population and the limited genotyping approach
which was not genome-wide. The combination of the 13 genetic and clinical parameters
improves the current methodology. Further investigation using a genome-wide approach on a
larger cohort would be necessary to capture additional weaker effects.
We identified two polymorphisms that had not previously been associated with the devel-
opment of VTE. We demonstrated that they are key in the development of VTE in CC users
and future studies will address their role in the general population. The first one (rs1799853) is
an established genetic markers in the field of pharmacogenetics also called 2. It affects the
activity of the enzyme CYP2C9 encoded by the corresponding gene. The cytochrome CYP2C9
is involved in the metabolism of ethynyl estradiol present in most of the combined pills [21].
We hypothesize that a decreased activity of the metabolism would lead to an increased sys-
temic level of ethynyl estradiol and therefore to an increased risk of coagulation. Interestingly,
the impact of this SNP on VTE in our data seems to be stronger than that of several previously
described markers.
The second novel polymorphism (rs4379368) is present in the gene coding for another
enzyme SUGCT. This transferase has been previously associated with migraine susceptibility
using genome-wide association study [22]. It is well established that migraine is a risk factor
for arterial diseases [23] and more recently migraine has also been associated with the develop-
ment of VTE [24]. The combination of migraine and hormone treatment increases further the
risk of cardiovascular diseases. It remains to determine, however, whether migraine as a risk
factor would improve the performance of our combined model because the information was
not available in our population.
The combination of the nine SNPs identified here as well as the identification of two SNPs
newly associated with VTE is specific to women who use CC due to the study design. Hence
further studies will be performed to confirm that these two novel SNPs and their combination
would also associate with VTE in the general population.
Our model selection has three key aspects: (1) Excluding individuals with missing values
would have drastically reduced the available sample size. Hence, we chose to perform 10,000
random imputations of the missing data and averaged results over the various randomly filled
data sets. One could have envisioned more sophisticated data imputation, but multivariate lin-
ear imputation of the missing data would not have improved the multivariate predictive model
performance. (2) To perform out-of-sample evaluation we used a cross-validation framework,
Thrombosis risk and contraception
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where for each of the 10,000 sets we split the data into two equally-sized groups and used one
group (‘training set’) to estimate the coefficients and the other group (‘test set’) to provide pre-
dictions for the AUC. We could have reported the results from a single data split, however that
would not have used optimally the available data and would be prone to random fluctuations
depending on the split. (3) The individual p-values of the selected 13 variables survive 5% FDR
control (given the total number of tested variables); hence less than one of them is expected to
be a false positive finding. Our cross-validation framework (with zeroing out the coefficients
of unselected variables) was designed to protect our coefficient estimates from winners curse.
Further work will establish meaningful clinical thresholds in order to translate this model into
a clinical test.
In conclusion, we identified new genetic markers for VTE development among CC users
and determined a new and robust combination of clinical and genetic parameters to predict
VTE risk in CC users. Although further validation in independent populations should be
envisaged, this combination outperforms all previously published genetic risk score in our
cross-validation setting.
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